Read More

ChromaDex Shares Promising Findings From A Clinical Study Showcasing Combined Metabolic Activators, Featuring Nicotinamide Riboside, Improved Cognitive Functions In Alzheimer’s Disease Patients

This first-of-its-kind human clinical study in AD patients showcased CMA supplementation significantly improved cognitive function and associated biomarkers ChromaDex Corp. (NASDAQ:CDXC), a global bioscience company

CDXC